U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H20FN2O4S.Na
Molecular Weight 438.448
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RAMATROBAN SODIUM

SMILES

[Na+].[O-]C(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4

InChI

InChIKey=JRBVAOJTPBHRQQ-XFULWGLBSA-M
InChI=1S/C21H21FN2O4S.Na/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26;/h1-6,8-9,15,23H,7,10-13H2,(H,25,26);/q;+1/p-1/t15-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C21H20FN2O4S
Molecular Weight 415.458
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ramatroban is a dual antagonist of thromboxane A2 receptor and PGD2 receptor. The drug was developed by Bayer and tested for the treatment of asthma and allergic rhinitis. In Japan ramatroban reached final approval and is being marketed under the name Baynas. In vitro studies have shown that the drug effectively inhibits smooth muscle cells contraction.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Ramatroban and its labeled metabolites did hardly penetrate the blood-brain barrier.

Originator

Bayer
156
Curator's Comment: # Bayer

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 10.0 nM [Ki]
Antagonist
2778
 30.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
BAYNAS

Approved Use

Treatment of Allergic rhinitis.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats.
2003 Nov
Patents

Patents

JP2004002353A
2

Sample Use Guides

In Vivo Use Guide
75 mg is administered orally devided in two doses, after breakfast and after dinner (or before going to bed).
Route of Administration: Oral
In Vitro Use Guide
Human airway smooth muscle preparations and lung strips were treated wuth 10(-6), 10(-7) and 10(-8) M of remetroban to inhibit U46619-induced contractions.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:10 GMT 2023
Edited
by admin
on Fri Dec 15 15:30:10 GMT 2023
Record UNII
5J3I129AXS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RAMATROBAN SODIUM
Common Name English
9H-CARBAZOLE-9-PROPANOIC ACID, 3-(((4-FLUOROPHENYL)SULFONYL)AMINO)-1,2,3,4-TETRAHYDRO-, SODIUM SALT (1:1), (3R)-
Systematic Name English
RAMATROBAN SODIUM SALT
Common Name English
Code System Code Type Description
CAS
1040405-44-4
Created by admin on Fri Dec 15 15:30:10 GMT 2023 , Edited by admin on Fri Dec 15 15:30:10 GMT 2023
PRIMARY
PUBCHEM
67027609
Created by admin on Fri Dec 15 15:30:10 GMT 2023 , Edited by admin on Fri Dec 15 15:30:10 GMT 2023
PRIMARY
FDA UNII
5J3I129AXS
Created by admin on Fri Dec 15 15:30:10 GMT 2023 , Edited by admin on Fri Dec 15 15:30:10 GMT 2023
PRIMARY
Related Record Type Details
Structure of RAMATROBAN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of RAMATROBAN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966